Adenocarcinoma of the Gastroesophageal Junction or Gastric
Showing 1 - 25 of 7,448
Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer Trial in Kyiv (Docetaxel, Oxaliplatin, Leucovorin)
Recruiting
- Gastric Cancer
- +10 more
- Docetaxel
- +3 more
-
Kyiv, UkraineNational Cancer Institute
Aug 31, 2023
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)
Not yet recruiting
- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Cadonilimab
- +5 more
- (no location specified)
Jul 17, 2023
Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (PD-1 inhibitor)
Recruiting
- Gastric or Gastroesophageal Junction Adenocarcinoma
- PD-1 inhibitor
-
Guangzhou, ChinaSun Yat-sen University Cancer Center
Aug 9, 2023
Gastric / Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (envafolimab and lenvatinib combined with
Enrolling by invitation
- Gastric / Gastroesophageal Junction Adenocarcinoma
- envafolimab and lenvatinib combined with paclitaxel-albumin
-
Shanghai, Shanghai, ChinaFudan University Cancer Hospital
Sep 3, 2023
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (XELOX combined with Fruquintinib and Sintilimab)
Not yet recruiting
- Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
- XELOX combined with Fruquintinib and Sintilimab
- (no location specified)
Oct 17, 2023
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)
Not yet recruiting
- HER2-positive Advanced Gastric Cancer
- HER2-positive Gastroesophageal Junction Adenocarcinoma
- Trastuzumab deruxtecan
- (no location specified)
Aug 11, 2023
Gastric Cancer Trial (S-1, Oxaliplatin, Cadonilimab)
Not yet recruiting
- Gastric Cancer
- S-1, Oxaliplatin, Cadonilimab
- (no location specified)
Jul 10, 2023
Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1
Active, not recruiting
- Gastric or Gastroesophageal Junction Adenocarcinoma
- neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Jul 4, 2023
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/
Not yet recruiting
- HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- SHR-A1811
- Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
- (no location specified)
Nov 6, 2023
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Capecitabine, oxaliplatin, Disitamab Vedotin)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Capecitabine
- +3 more
-
Beijing, Beijing, China
- +10 more
Nov 23, 2023
Gastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction Trial in Guangzhou (Docetaxel for injection (Albumin-bound),
Recruiting
- Gastric Adenocarcinoma
- Adenocarcinoma of Gastroesophageal Junction
- Docetaxel for injection (Albumin-bound)
- Taxotere
-
Guangzhou, ChinaEthics Committee of Sun-Yat-Sen University Cancer Center
Jan 27, 2023
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric
Available
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer
- +3 more
-
Morristown, New JerseyAMG Hematology/Oncology
Sep 15, 2023
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial (Ramucirumab, Paclitaxel)
No longer available
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- (no location specified)
Jan 17, 2023
Adenocarcinoma, Stomach Tumor, Gastroesophageal-junction Cancer Trial in Shanghai (radiation, biological, drug, procedure)
Recruiting
- Adenocarcinoma
- +8 more
- Radiotherapy targeted to the primary lesion
- +7 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 7, 2023
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma Trial
Not yet recruiting
- Advanced Esophageal Adenocarcinoma
- +14 more
- Fluorouracil
- +8 more
- (no location specified)
Jan 3, 2023
HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811;SHR-1701;capecitabine;oxaliplatin)
Not yet recruiting
- HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
- (no location specified)
Jan 3, 2023
Gastric Cancer, GastroEsophageal Cancer, Fruquintinib Trial in Nanning (Fruquintinib + SOX)
Recruiting
- Gastric Cancer
- +3 more
- Fruquintinib + SOX
-
Nanning, ChinaGuangxi Medical University Cancer Hospital
Dec 2, 2022
Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal Junction (GEJ) Cancer
- T-Dxd(Trastuzmab deruxtecan), Ramucirumab
- (no location specified)
Jun 7, 2023
Adenocarcinoma of Stomach Trial in Shanghai (Gentuximab Injection, Gentuximab Injection Placebo)
Recruiting
- Adenocarcinoma of Stomach
- Gentuximab Injection
- Gentuximab Injection Placebo
-
Shanghai, Shanghai, ChinaShanghai Dongfang Hospital
Jun 16, 2023
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) Trial in Tianjin (Serplulimab+Paclitaxel+Apatinib,
Recruiting
- Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jul 5, 2023
Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer Trial (LB1908)
Not yet recruiting
- Gastric Cancer
- +3 more
- LB1908
- (no location specified)
Sep 9, 2022
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial (pembrolizumab, cisplatin, 5-FU)
Completed
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- pembrolizumab
- +3 more
- (no location specified)
Jul 13, 2022
Gastric Cancer, Gastroesophageal-junction Cancer Trial in Wuhan, Nanjing, Taiyuan (Tislelizumab, S-1, Oxaliplatin)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Tislelizumab
- +4 more
-
Wuhan, Hubei, China
- +2 more
Jan 16, 2023
Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Chuo Ku (TRK-950, Ramucirumab,
Not yet recruiting
- Gastric Adenocarcinoma
- +2 more
- TRK-950
- +2 more
-
Chuo Ku, JapanOsaka International Cancer Institute
Sep 14, 2023